Atara Biotherapeutics, Inc.
ATRA
$7.32
-$0.28-3.68%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -85.40M | -133.16M | -181.05M | -233.11M | -276.13M |
| Total Depreciation and Amortization | 5.05M | 5.16M | 5.14M | 5.01M | 4.83M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 42.59M | 49.18M | 54.33M | 59.89M | 62.98M |
| Change in Net Operating Assets | -30.96M | -15.83M | -20.42M | -15.94M | 15.34M |
| Cash from Operations | -68.72M | -94.65M | -142.01M | -184.16M | -192.98M |
| Capital Expenditure | -246.00K | -200.00K | -481.00K | -951.00K | -1.22M |
| Sale of Property, Plant, and Equipment | -- | 0.00 | 25.00K | 25.00K | 25.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 8.87M | 15.39M | 102.76M | 145.52M | 125.06M |
| Cash from Investing | 8.62M | 15.19M | 102.30M | 144.59M | 123.87M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -892.00K | -872.00K | -883.00K | -862.00K | -947.00K |
| Issuance of Common Stock | 60.28M | 62.01M | 11.19M | 11.80M | 3.06M |
| Repurchase of Common Stock | -99.00K | -6.00K | -6.00K | -7.00K | -94.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -7.00K | -7.00K | 14.82M | 14.99M | -13.00K |
| Cash from Financing | 59.28M | 61.12M | 25.12M | 25.92M | 2.01M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -811.00K | -18.34M | -14.58M | -13.65M | -67.10M |